Initial experience with ribavirin plus glycyrrhizin in renal allograft recipients with chronic hepatitis C [2]

Indian Journal of Gastroenterology

Volumn 23, Issue 6, 2004, Pages 226-227

  Anand, Anil C ^a,b   Seth, Avnish K ^a   Nagpal, Akhil ^a   Varma, Prem P ^a   Gadela, S R ^a   Baliga, K V ^a   Dutta, Vibha ^a   Chopra, G S ^a  

^a ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^b ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCYRRHIZIC ACID; RIBAVIRIN;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; LETTER; LIVER HISTOLOGY; MALE; MONOTHERAPY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GLYCYRRHIZIC ACID; HEPATITIS C, CHRONIC; HUMANS; KIDNEY TRANSPLANTATION; MALE; RIBAVIRIN;

EID: 11844255634     PISSN: 02548860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Morales JM, Campistol JM, Andres A, Rodicio JL. Hepatitis C virus and renal transplantation. Curr Opin Nephrol Hypertens 1998;7.2:177-83.
2. Orloff SL, Stempel CA, Wright TL, Tomlanovich SJ, Amend WJ, Stock PG, et al. Long-term outcome in kidney transplant patients with hepatitis C (HCV) infection. Clin Transplant 1995;9:119-24.
3. Ozdogan M, Ozgur O, Gur G, Boyacioglu S, Ozderin Y, Demirhan B, et al. Histological impact of hepatitis virus infection in hemodialysis patients: should liver biopsy be performed before renal transplantation? Artif Organs 1997;21:355-8.
4. Magnone M, Holley JL, Shapiro R, Scantlebury V, McCauley J, Jordan M, et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995;59:1068-70.
5. Daoud S, Garnier JL, Chossegros P, Chevallier P, Dubernard JM, Touraine JL. Hepatitis C virus infection in renal transplantation. Transplant. Proc 1995;27:1735.
6. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al, and Osaka Liver Disease Study Group. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998;27:1394-402.
7. Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida I, et al. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997;79:1494-500.
8. Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin (stronger neo-minophagen C [SNMC]) for preventing liver cirrhosis and hepatocellular carcinoma. Oncology 2002;62(Suppl 1):94-100.
9. Knodell RG, Ishak K, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.